Prateek Gulhati, MD, PhD
New Brunswick, N.J., January 4, 2023 – Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options. Researchers from Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, in collaboration with investigators from MD Anderson Cancer Center, discovered a novel triple immunotherapy combination, targeting checkpoints on both T cells and myeloid suppressor cells, that dramatically improved anti-tumor responses by reprogramming the tumor microenvironment in preclinical models of PDAC. Prateek Gulhati, MD, PhD, physician-scientist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School is the lead author of the work and shares more about the findings published in Nature Cancer (https://doi.org/10.1038/s43018-022-00500-z).
Why is this topic important?
PDAC is one of the leading causes of cancer death in the United States and is considered to be “non-immunogenic,” which means it is unresponsive to commonly used anti-PD-1 and anti-CTLA-4 immune checkpoint therapy. This is partly due to the immunosuppressive conditions in the tumor microenvironment, but the mechanisms behind this resistance are not well understood.
How was the study structured and what did you and your colleagues find?
We used comprehensive immune profiling in mouse and human pancreatic cancers to systematically identify mechanisms of immunotherapy resistance and investigate potential new therapeutic targets. We found that neutralizing several distinct immunosuppressive mechanisms in the tumor microenvironment dramatically improved anti-tumor responses. We identified a new immunotherapy combination regimen that resulted in tumor regression and improved survival in preclinical models of pancreatic cancer.
What are the implications of these findings?
Our findings suggest that pancreatic cancer patients may benefit from the right combination of immunotherapy drugs. These results are encouraging and we remain optimistic that pancreatic cancer, and other “non-immunogenic” cancers, will ultimately be rendered vulnerable to combination immunotherapy.
What are future steps pertaining to this work?
Prospective clinical trials will be needed to substantiate the hypothesis generated from this work and evaluate this combination immunotherapy regimen for treatment of PDAC patients. The targets identified in this study are present in a significant proportion of pancreatic cancer patient specimens, which raises the possibility that such a regimen may be worth investigating in a clinical trial. We are continuing our research to identify new mechanisms of resistance to immunotherapy and uncovering new vulnerabilities to target pancreatic cancer.
Author acknowledgements, disclosures and other information can be found here.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
732-507-8307
krista.didzbalis@rutgers.edu
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)